Skip to main content
SpringerLink
Log in

Endometrial Cancer Genetic Classification and Its Clinical Application

  • Chapter
  • First Online:
Management of Endometrial Cancer

  • 715 Accesses

Abstract

Each year, epithelial endometrial cancer (EC) incidence accounts for 7% of all cancers in women worldwide, representing the fourth most common malignancy arising in women. In the United States alone, over 54,000 new cases are expected and over 10,170 women will die of this disease in 2015 [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  2. Silverberg SG, Kurman RJ, Nogales F, et al. Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, editors. World Health Organization classification of tumours: pathology and genetics—tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 217–32.

    Google Scholar 

  3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.

    Article  CAS  PubMed  Google Scholar 

  4. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol. 1997;81:228–32.

    CAS  PubMed  Google Scholar 

  5. Potischman N, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88:1127–35.

    Article  CAS  PubMed  Google Scholar 

  6. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58(15):3254–8.

    CAS  PubMed  Google Scholar 

  7. Colombo N, Preti E, Landoni F, Carinelli S, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Supplement 6):vi33–8.

    PubMed  Google Scholar 

  8. Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol. 2008;20(1):26–33.

    Article  PubMed  Google Scholar 

  9. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14(8):2263–9.

    Article  CAS  PubMed  Google Scholar 

  11. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15(7):e268–78.

    Article  PubMed  Google Scholar 

  12. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129:277–84.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic diff erences. Am J Surg Pathol. 2007;31:979–87.

    Article  PubMed  Google Scholar 

  14. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2013;37(6):874–81.

    Article  PubMed  Google Scholar 

  16. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability diff ers in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814–24.

    Article  CAS  PubMed  Google Scholar 

  17. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261–71.

    Article  CAS  PubMed  Google Scholar 

  18. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011;71:4061–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1:170–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Santin AD, Bellone S, Van Stedum S, et al. Amplifi cation of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104:1391–7.

    Article  CAS  PubMed  Google Scholar 

  21. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression ofEGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994;53:84–92.

    Article  CAS  PubMed  Google Scholar 

  22. Byron SA, Gartside MG, Wellens CL, et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008;68(17):6902–7.

    Article  CAS  PubMed  Google Scholar 

  23. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011;2(3):261–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Schlosshauer PW, Ellenson LH, Soslow RA. β-Catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002;15:1032–7.

    Article  PubMed  Google Scholar 

  25. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62:111–23.

    Article  PubMed  Google Scholar 

  26. Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M, Inoue M. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene. 2003;22(15):2352–60.

    Article  CAS  PubMed  Google Scholar 

  27. Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013;14(6):e229–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Shih Ie M, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones S, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol. 2011;178(4):1442–7.

    Article  PubMed  Google Scholar 

  30. Pere H, Tapper J, Wahlstrom T, et al. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas. Cancer Res. 1998;58:892–5.

    CAS  PubMed  Google Scholar 

  31. Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2001;91:22–6.

    Article  CAS  PubMed  Google Scholar 

  32. Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene. 2002;21:7981–90.

    Article  CAS  PubMed  Google Scholar 

  33. Liao X, Siu MK, Chan KY, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer. 2008;123:296–302.

    Article  CAS  PubMed  Google Scholar 

  34. Yi TZ, Guo J, Zhou L, et al. Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. Cancer Investig. 2011;29:86–92.

    Article  CAS  Google Scholar 

  35. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814–24.

    Article  CAS  PubMed  Google Scholar 

  36. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW. A unique spectrum of somatic PIK3CA (p110α) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011;17:1331–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1:170–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65:10669–73.

    Article  CAS  PubMed  Google Scholar 

  39. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008;Chapter 10:Unit 10.11.

    CAS  PubMed  Google Scholar 

  40. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One. 2012;7:e30801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, Prat J. CTNNB1 mutations and β-catenin expression in endometrial carcinomas. Hum Pathol. 2002;33:206–12.

    Article  CAS  PubMed  Google Scholar 

  42. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224:328–33.

    Article  CAS  PubMed  Google Scholar 

  43. O’Hara AJ, Bell DW. The genomics and genetics of endometrial cancer. Adv Genomics Genet. 2012;2012:33–47.

    PubMed  PubMed Central  Google Scholar 

  44. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104:1503–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, et al. Landscape of somatic singlenucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013;110:2916–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med. 2012;4:808–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011;17(6):1331–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. McConechy MK, Anglesio MS, Kalloger SE, for the Australian Ovarian Cancer Study Group, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 2011;223:567–73.

    Article  CAS  PubMed  Google Scholar 

  49. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci. 2001;943:296–315.

    Article  CAS  PubMed  Google Scholar 

  50. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21(3):427–33.

    Article  CAS  PubMed  Google Scholar 

  51. Lebeau A, et al. Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J Pathol. 2008;216:151–7.

    Article  CAS  PubMed  Google Scholar 

  52. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004;10(1 Pt 2):331S–6S.

    Article  CAS  PubMed  Google Scholar 

  53. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, Chen S, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11(14):5319–28.

    Article  CAS  PubMed  Google Scholar 

  54. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.

    Article  CAS  PubMed  Google Scholar 

  55. Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009;112(3):537–42.

    Article  CAS  PubMed  Google Scholar 

  56. Kohler MF, et al. Mutational analysis of the estrogen-receptor gene in endometrial carcinoma. Obstet Gynecol. 1995;86:33–7.

    Article  CAS  PubMed  Google Scholar 

  57. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W, Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10–4.

    Article  CAS  PubMed  Google Scholar 

  58. The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.

    Article  CAS  Google Scholar 

  59. Le Gallo M, Bell DW. The emerging genomic landscape of endometrial cancer. Clin Chem. 2014;60(1):98–110.

    Article  PubMed  CAS  Google Scholar 

  60. Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014;106(9):dju245.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.

    Article  PubMed Central  CAS  Google Scholar 

  62. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Article  PubMed Central  CAS  Google Scholar 

  63. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014;138(3):343–50.

    Article  PubMed  Google Scholar 

  65. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15–20. https://doi.org/10.1016/j.ygyno.2009.09.025.

    Article  CAS  PubMed  Google Scholar 

  66. Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012;127:345–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319–25.

    Article  CAS  PubMed  Google Scholar 

  68. Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129:486–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105:8713–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26:7158–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2014;135(3):441–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Powell MA, Sill MW, Goodfellow PJ, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2014;135(1):38–43. https://doi.org/10.1016/j.ygyno.2014.07.083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 2015;16(6):686–94.

    Article  CAS  PubMed  Google Scholar 

  74. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106(12):4834–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Kanamori Y, Kigawa J, Itamochi H, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res. 2001;7:892–5.

    CAS  PubMed  Google Scholar 

  77. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116:5415–9.

    Article  CAS  PubMed  Google Scholar 

  78. Ray-Coquard I, Favier L, Weber B, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer. 2013;108:1771–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014;24(4):713–7.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Colombo N, McMeekin S, Schwartz P, Kostka J, Sessa C, Gehrig P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2007;25:278s. (abstr 5516).

    Google Scholar 

  81. Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer. 2013;108(5):1021–6. https://doi.org/10.1038/bjc.2013.59. Epub 2013 Feb 12.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135(2):184–9.

    Article  CAS  PubMed  Google Scholar 

  83. Oza AM, Pignata S, Poveda A, et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33:3576–82. [Epub ahead of print].

    Article  CAS  PubMed  Google Scholar 

  84. Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 2014;120(4):603–10.

    Article  CAS  PubMed  Google Scholar 

  85. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J Clin Oncol. 2011;29:3278–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Goodwin RA, Jamal R, Tuc D, et al. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2013;13:315–20.

    Article  CAS  Google Scholar 

  87. Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2014;132:585–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129:22–7.

    Article  CAS  PubMed  Google Scholar 

  89. André F, O’Regan R, Mustafa Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580–91.

    Article  PubMed  CAS  Google Scholar 

  90. Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Bradford LS, Rauh-Hain A, Clarka RM, et al. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecol Oncol. 2014;133:346–52.

    Article  CAS  PubMed  Google Scholar 

  92. Heudel PE, Fabbro M, Roemer-Becuwe C, et al. Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO study. J Clin Oncol. 2015;33:5588. (suppl; abstr 5588).

    Article  Google Scholar 

  93. Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136(2):246–53.

    Article  CAS  PubMed  Google Scholar 

  94. Makker V, Recio FO, Ma L, Matulonis U, O’Hara Lauchle J, Parmar H, et al. Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: final study results. J Clin Oncol. 2014;32:5513. [Abstr].

    Article  Google Scholar 

  95. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143–53.

    Article  CAS  PubMed  Google Scholar 

  96. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6–7):315–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predict sensitivity to PARP-inhibitors. Sci Transl Med. 2010;2(53):53ra75.

    Article  PubMed  CAS  Google Scholar 

  98. Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol. 2011;8(5):302–6. https://doi.org/10.1038/nrclinonc.2011.42. Epub 2011 Apr 5.

    Article  CAS  PubMed  Google Scholar 

  99. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res. 2003;9(4):1361–9.

    CAS  PubMed  Google Scholar 

  100. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65. https://doi.org/10.1200/JCO.2010.32.6397. Epub 2011 May 2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Aghajanian CA, Filaci VL, Dizon DS, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol. 2015;33. (suppl; abstr 5500).

    Article  Google Scholar 

  102. Lorusso D, Ferrandina G, Colombo N, et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. J Clin Oncol. 2015;33. (suppl; abstr 5502).

    Article  Google Scholar 

  103. Myers AP, Broaddus R, Makker V, Konstantinopoulos PA, Drapkin R, Horowitz NS, et al. Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). J Clin Oncol. 2013;31:5524. [Suppl.; abstr].

    Google Scholar 

  104. Konstantinopoulos P, Makker V, Barry WT, Liu J, Horowitz NS, Birrer MJ, et al. Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. J Clin Oncol. 2014;32:5515. [Abstr].

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Cancer Research, The Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Lorenzo Ceppi, Don S. Dizon & Michael J. Birrer

  2. Department of Medicine and Surgery, Milano-Bicocca University, ASST-Monza, Desio Hospital, Monza and Brianza, Italy

    Lorenzo Ceppi

  3. O’Neal Cancer Center, Birmingham, AL, USA

    Michael J. Birrer

Authors
  1. Lorenzo Ceppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Don S. Dizon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Birrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Birrer .

Editor information

Editors and Affiliations

  1. Rigshospitalet, Copenhagen University Rigshospitalet, København Ø, Denmark

    Mansoor R. Mirza

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ceppi, L., Dizon, D.S., Birrer, M.J. (2020). Endometrial Cancer Genetic Classification and Its Clinical Application. In: Mirza, M. (eds) Management of Endometrial Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-64513-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64513-1_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64512-4

  • Online ISBN: 978-3-319-64513-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation